Arvinas IncARVN

ARVN current price
$28.04+69.02%

Capital at risk.

1W
+6.66%
1M
+6.62%
3M
+15.96%
6M
-10.59%
1Y
+69.02%
MAX
+74.70%
About Arvinas Inc
Ticker
info
ARVN
Trading on
info
NASDAQ
ISIN
info
US04335A1051
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Dr. John G. Houston Ph.D.
Headquarters
info
5 Science Park, New Haven, CT, United States, 06511
Employees
info
445
Website
info
arvinas.com
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Metrics
BasicAdvanced
Market cap
info
$1.86B
P/E ratio
info
-
EPS
info
-$4.79
Dividend Yield
info
0.00%
Beta
info
1.97
Forward P/E ratio
info
17.7
EBIDTA
info
$-353M
Ex dividend date
info
-
Price & volume
Market cap
info
$1.86B
Average daily volume
info
0.6M
90-day return
info
15.96%
30-day return
info
6.62%
7-day return
info
6.66%
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
17.7
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
11.58
Price to book
info
3.18
Earnings
EPS
info
-$4.79
EPS estimate (current quarter)
info
-$0.96
EPS estimate (next quarter)
info
-$1.02
EBITDA
info
$-353M
Revenues (TTM)
info
$161M
Revenues per share (TTM)
info
$2.33
Technicals
Beta
info
1.97
52-week High
info
$53.08
52-week Low
info
$17.12
50-day moving average
info
$25.76
200-day moving average
info
$32.26
Short ratio
info
17.66
Short %
info
13.81%
Management effectiveness
ROE (TTM)
info
59.16%
ROA (TTM)
info
20.07%
Profit margin
info
191.56%
Gross profit margin
info
$131M
Operating margin
info
58.89%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
196.00%
Share stats
Outstanding Shares
info
68.7M
Float
info
57.2M
Insiders %
info
7.22%
Institutions %
info
107.87%
Analyst Insights & forecasts
info

90% Buy

10% Hold

0% Sell

Based on information from 20 analysts.

Average price target

info
$63.61
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$2.53
-$1.27
99.21%
Q4 • 23Beat
-$0.97
-$1.42
31.69%
Q1 • 24Beat
-$0.49
-$0.86
43.02%
Q2 • 24Beat
-$0.68
-$0.96
29.17%
Q3 • 24Beat
-
-
-
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$76.5M
$-35.2M
46.01%
Q2 • 24
$102M
$-49.2M
48.05%
Q3 • 24
33.86%
39.77%
4.42%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$1.28B
$679M
53.09%
Q2 • 24
$1.17B
$581M
49.79%
Q3 • 24
8.79%
14.47%
6.22%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$50.3M
$13.1M
$3.4M
$49.6M
Q2 • 24
$-128M
$50.5M
$2.4M
$-129M
Q3 • 24
354.47%
285.50%
29.41%
359.48%
QoQ growth
QuarterlyAnnual
Sentiment analysis

-1.5

Neutral

+1.5

-0.25

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Arvinas Inc share?
Collapse

Arvinas Inc shares are currently traded for $28.04 per share.

How many shares does Arvinas Inc have?
Collapse

Arvinas Inc currently has 68.7M shares.

Does Arvinas Inc pay dividends?
Collapse

No, Arvinas Inc doesn't pay dividends.

What is Arvinas Inc 52 week high?
Collapse

Arvinas Inc 52 week high is $53.08.

What is Arvinas Inc 52 week low?
Collapse

Arvinas Inc 52 week low is $17.12.

What is the 200-day moving average of Arvinas Inc?
Collapse

Arvinas Inc 200-day moving average is $32.26.

Who is Arvinas Inc CEO?
Collapse

The CEO of Arvinas Inc is Dr. John G. Houston Ph.D..

How many employees Arvinas Inc has?
Collapse

Arvinas Inc has 445 employees.

What is the market cap of Arvinas Inc?
Collapse

The market cap of Arvinas Inc is $1.86B.

What is the P/E of Arvinas Inc?
Collapse

The current P/E of Arvinas Inc is null.

What is the EPS of Arvinas Inc?
Collapse

The EPS of Arvinas Inc is -$4.79.

What is the PEG Ratio of Arvinas Inc?
Collapse

The PEG Ration of Arvinas Inc is null.

What do analysts say about Arvinas Inc?
Collapse

According to the analysts Arvinas Inc is considered a buy.

Arvinas Inc news